Phase II Study of Vinorelbine and Estramustine in Combination With Conformational Radiotherapy for Patients With High-Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 4, 2010, Pages 1085-1091

  Carles, Joan ^a   Nogue, Miguel ^b   Sole, Josep M ^c   Foro, Palmira ^d   Domenech, Montserrat ^e   Suarez, Marta ^a   Gallardo, Enrique ^f   García, Darío ^b   Ferrer, Ferrán ^d   Gelabert Mas, Antoni ^a   Gayo, Javier ^g   Fabregat, Xavier ^a  

^a HOSPITAL DEL MAR   (Spain)

^b Parc Tauli Health Corporation   (Spain)

^c HOSPITAL GENERAL DE CATALUNYA   (Spain)

^d HOSPITAL DE L ESPERANÇA   (Spain)

^e Hospital General de Manresa   (Spain)

^f HOSPITAL DE TERRASSA   (Spain)

^g Centre d'Immunologie Pierre Fabre   (France)

Author keywords

3D conformational radiotherapy; Estramustine phosphate; High risk prostate cancer; Vinorelbine

Indexed keywords

3D CONFORMATIONAL RADIOTHERAPY; ESTRAMUSTINE PHOSPHATE; PROSTATE CANCERS; VINORELBINE;

FLUORESCENT SCREENS; RADIOTHERAPY; TOXICITY;

THREE DIMENSIONAL;

DIURETIC AGENT; ESTRAMUSTINE PHOSPHATE; GONADORELIN DERIVATIVE; NAVELBINE;

ACUTE HEART INFARCTION; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENTERITIS; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PARALYTIC ILEUS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; SIDE EFFECT; URETHRA STRICTURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYSTITIS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; PROCTITIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REMISSION INDUCTION; SPAIN; VINBLASTINE;

EID: 77449137613     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.03.024     Document Type: Article

References (39)

1. Brenner H., and Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 23 (2005) 441-447
2. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 101 Suppl 2 (2008) 11-15
3. Gridelli C. The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 6 Suppl 1 (2001) 4-7
4. Gridelli C., Gallo C., Shepherd F.A., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 3025-3034
5. Zelek L., Barthier S., Riofrio M., et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92 (2001) 2267-2272
6. Le Chevalier T., Brisgand D., Soria J.C., et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6 Suppl 1 (2001) 8-11
7. Fields-Jones S., Koletsky A., Wilding G., et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 10 (1999) 1307-1310
8. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 15 (1997) 13-19
9. Hudes G., Einhorn L., Ross E., et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 17 (1999) 3160-3166
10. Albrecht W., Van Poppel H., Horenblas S., et al. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 90 (2004) 100-105
11. Carles J., Domenech M., Gelabert-Mas A., et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol 37 (1998) 187-191
12. Berry W.R., Hathorn J.W., Dakhil S.R., et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 3 (2004) 104-111
13. Oudard S., Banu E., Beuzeboc P., et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23 (2005) 3343-3351
14. Kim J.H., Khil M.S., Kim S.H., Ryu S., and Gabel M. Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 29 (1994) 555-557
15. Ryu S., Gabel M., Khil M.S., et al. Estramustine: A novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 30 (1994) 99-104
16. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
17. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
18. Diaz A., Roach M., Marquez C., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30 (1994) 323-329
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
20. National Cancer Institute. Common toxicity criteria, version 2.0 (1999), National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD p. 1-27
21. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
22. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21 (1991) 935-939
23. Carles Galceran J., Bastus Piulats R., Martin-Broto J., et al. A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer. Clin Transl Oncol 7 (2005) 66-73
24. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16 (1998) 1318-1324
25. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
26. Tepper J.E., O'Connell M.J., Petroni G.R., et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114. J Clin Oncol 15 (1997) 2030-2039
27. Khil M.S., Kim J.H., Bricker L.J., and Cerny J.C. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy. Cancer J Sci Am 3 (1997) 289-296
28. Ben-Josef E., Porter A.T., Han S., et al. Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. Int J Radiat Oncol Biol Phys 49 (2001) 699-703
29. Kumar P., Perrotti M., Weiss R., et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 22 (2004) 1909-1915
30. Strnad V., Riepl M., Kuhn R., and Sauer R. [Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma]. Strahlenther Onkol 172 (1996) 225-228
31. Zelefsky M.J., Kelly W.K., Scher H.I., et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 18 (2000) 1936-1941
32. Ryan C.J., Zelefsky M.J., Heller G., et al. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology 64 (2004) 90-94
33. Rosenthal S.A., Bae K., Pienta K.J., et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: Preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys (2008)
34. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
35. Carles J., Font A., Mellado B., et al. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer 97 (2007) 1206-1210
36. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
37. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
38. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
39. Mangar S.A., Huddart R.A., Parker C.C., et al. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 41 (2005) 908-921